MoneyWorks4Me

Samrat Pharmachem - Quaterly Results

14 Feb 2025 Evaluate
The total revenue for the quarter ended December 2024 remained nearly unchanged at Rs. 636.61 millions.The Total revenue for the quarter ended December 2024 of  Rs. 27.85  millions  grew by 709.59% from Rs. 3.44 millions.Operating Profit saw a handsome growth to 41.75 millions from 5.34 millions in the quarter ended December 2024.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 636.61 616.74 3.22 2146.57 1988.99 7.92 2815.81 3106.46 -9.36
Other Income 0.04 4.21 -99.05 10.81 10.85 -0.37 13.85 4.78 189.75
PBIDT 41.75 5.34 681.84 111.95 22.00 408.86 38.54 244.06 -84.21
Interest 0.96 2.31 -58.44 4.52 5.82 -22.34 6.87 12.32 -44.24
PBDT 40.79 3.03 1246.20 107.43 16.18 563.97 31.67 231.74 -86.33
Depreciation 1.66 1.62 2.47 4.94 4.87 1.44 6.47 6.43 0.62
PBT 39.13 1.41 2675.18 102.49 11.31 806.19 25.20 225.31 -88.82
TAX 11.28 -2.03 -655.67 27.38 3.65 650.14 3.57 59.00 -93.95
Deferred Tax 2.46 -3.11 -179.10 -1.75 0.03 -5933.33 0.82 -2.07 -139.61
PAT 27.85 3.44 709.59 75.11 7.66 880.55 21.63 166.31 -86.99
Equity 30.90 30.90 0.00 30.90 30.90 0.00 30.90 30.90 0.00
PBIDTM(%) 6.56 0.87 657.47 5.22 1.11 371.50 1.37 7.86 -82.58
Peers
Company Name CMP
Sun Pharma. Inds. 1853.00
Dr. Reddys Labs. 1200.40
Cipla 1404.00
Lupin 2098.00
Zydus Lifesciences 1180.00
View more..